Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept (ACTFRIE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00811681|
Recruitment Status : Completed
First Posted : December 19, 2008
Last Update Posted : September 4, 2013
Friedreich's ataxia (FA) is a rare progressive neurological disorder affecting approximately 1/30, 000 individuals. No treatment is presently available to counteract the neurodegeneration of this extremely severe disease.
Pioglitazone, a well known PPAR gamma (peroxysome proliferators-activated receptor gamma) ligand induces the expression of many enzymes involved in the mitochondrial metabolism, including the superoxide dismutases. This agent may be therapeutic by counteracting the disabled recruitment of antioxidant enzymes in FA patients. This potential neuroprotective agent crosses the brain blood barrier in human.
Primary objective: To explore the effects of Pioglitazone on neurological function in FA patients. We expect neurological benefits taking into account the natural course of the disease.
Population: Subjects for this study will be limited to patients not older than 25 years Methodology: Prospective, randomized double-blind trial of Pioglitazone versus placebo in FA patients. Patients will be treated two years and will undergo clinical exams and testing during three days each six months at the clinical investigation centre.
|Condition or disease||Intervention/treatment||Phase|
|Friedreich's Ataxia||Drug: pioglitazone Drug: Placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Effect of Pioglitazone Administered to Patients With Friedreich's ATAXIA:Proof of Concept|
|Study Start Date :||December 2008|
|Actual Primary Completion Date :||March 2013|
|Actual Study Completion Date :||March 2013|
administered orally once a day after the first visit and for a total of 2 years. Initially, Pioglitazone will be started at 15mg /day. Dosage will then increase by 15mg /d/ week up to the maximal dose of 45mg /day
Placebo Comparator: Control
a placebo administered orally once a day after the first visit and for a total of 2 years.
Other Name: Control
- evaluate the efficacy of Pioglitazone on the neurological function of FA patients. Success will be defined as a stabilisation or improvement on ICARS designed as no more than 2 points maximum increment on this scale in two year. [ Time Frame: 2 years ]
- tolerance of Pioglitazone [ Time Frame: 2 years ]
- efficacy of Pioglitazone on neurological function [ Time Frame: 2 years ]
- efficacy of Pioglitazone on functional handicap and quality of life [ Time Frame: 2 years ]
- effect of Pioglitazone on cardiac parameters [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00811681
|Hôpital Robert Debré|
|Paris, France, 75019|
|Principal Investigator:||Isabelle Husson||Assistance Publique - Hôpitaux de Paris|